GLP1R and type 2 diabetes mellitus: As such, exenatide was the first GLP‐1 receptor ligand drug approved for type 2 diabetes in 2005 as a twice‐daily preparation (Nielsen et al., 2004) and was swiftly followed by approval of once‐daily liraglutide (Drucker et al., 2010).